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Design: Nationwide, retrospective multicenter study.
Setting: Five University Hospitals.
Participants: The nationwide FinnValve registry included data from 2,130 patients who underwent TAVR for aortic stenosis from 2008 to 2017.
After excluding patients who underwent TAVR through nontransfemoral accesses, 1,818 patients were selected for this analysis.
Intervention: TAVR with or without coronary revascularization.
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Conclusions: Patients who received blood transfusion after TAVR had an increased risk of early and late adverse events. These adverse effects
were particularly evident with increasing amount of RBC transfusion and operations for excessive bleeding.
 2019 Elsevier Inc. All rights reserved.
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three- to six-fold increase in the use of transcatheter aortic valve
replacement (TAVR) procedures for severe aortic stenosis (AS) in
previous years.1,2 The widespread use of TAVR paralleled with a
larger number of patients being referred for invasive treatment of
AS with a documented improvement of early and midterm sur-
vival.2 Interestingly, these studies showed a significant decrease in
the rates of red blood cell (RBC) transfusion after TAVR during
the most recent years.1-3 Still, a few previous studies4-8 docu-
mented a high frequency of RBC transfusion after TAVR with a
negative impact on the outcome. However, most of these studies
were institutional series of limited size with short follow-up and
without a thorough analysis of important bleeding-related varia-
bles, such as the amount of RBC transfusions, need of operation
to treat severe bleeding, or drop of hemoglobin level. The authors
aimed to investigate the impact of these parameters on patient out-
come in a nationwide TAVR registry.
Materials and Methods
Study Population
The FinnValve registry is a nationwide registry registered in
ClinicalTrials.gov (Identifier: NCT03385915), which retrospec-
tively collects data from consecutive and unselected patients who
underwent TAVR or surgical aortic valve replacement with a bio-
prosthesis for severe AS with or without myocardial revasculari-
zation at all 5 Finnish university hospitals (Helsinki, Kuopio,
Oulu, Tampere, and Turku) from January 2008 to October 2017.
During the study period, both TAVR and surgical aortic valve
replacement were performed only in these university hospitals. A
limited number of TAVR procedures have been performed in 3
central hospitals without onsite cardiac surgery over a short
period of time when temporarily allowed by the national authori-
ties. Data from these central hospitals were not collected into this
registry to avoid bias related to procedures performed outside a
heart team environment. This study was approved by the institu-
tional review board of each participating center.
The inclusion criteria for this study were (1) transfemoral
TAVR for AS with or without aortic valve regurgitation; (2)
patients aged >18 years; and (3) primary TAVR with or without
concomitant coronary revascularization. The exclusion criteria
were (1) prior TAVR or surgical intervention on the aortic
valve; (2) transcatheter or surgical procedure for isolated aortic
valve regurgitation; (3) acute endocarditis; and (4) TAVR per-
formed through other than transfemoral access.
Data was collected retrospectively into an electronic case
report form by cardiologists, cardiac surgeons, and research
nurses. Data underwent robust checking of its completeness andquality. Data on mortality was retrieved from the national regis-
try Statistics Finland, which is based on death certificates
reviewed by local authorities. Based on this, follow-up was con-
sidered complete for all patients, but for those not residing in
Finland whose follow-up was truncated at hospital discharge.
Transfusion Policy
The criteria for blood transfusion in this study were not pre-
specified. However, during the study period, all centers
adopted a policy of transfusing RBC when hemoglobin was
9.0 g/dL during the day of procedure and 8.0 g/dL during
the subsequent days.
Definition Criteria of Baseline Risk Factors
Baseline variables were defined according to the Euro-
SCORE II criteria.9 The operative risk of these patients was
stratified according to the EuroSCORE II and the Society of
Thoracic Surgeons (STS)10 risk scores. Severe frailty was
defined according to the Geriatric Status Scale (GSS) and
herein is defined as GSS grades 2 to 3 as proposed by Rock-
wood et al.11 Anemia was defined according to the World
Health Organization criteria (ie, <12 g/dL in women,
<13 g/dL in men). Coronary artery disease was defined as any
stenosis 50% of the main coronary branches. Selected valve
prostheses were the following third generation TAVR prosthe-
ses and their variants: Evolut R (Medtronic, Minneapolis,
MN), Sapien 3 (Edwards, Irvine, CA), Acurate Neo (Boston
Scientific, Marlborough, MA), and Lotus (Boston Scientific).
Stratification of the Severity of Perioperative Bleeding
The severity of perioperative bleeding were stratified accord-
ing to different criteria as follows: (1) any RBC transfusion; (2)
amount of transfused RBC units perioperatively and during the
index hospitalization; (3) transfusion of 4 RBC units and any
operation for intrathoracic or access site bleeding; (4) increasing
amount of RBC transfusions (ie, no RBC transfusion, 1-2 RBC
units, 3-4 RBC units; >4 RBC units); (5) the Valve Academic
Research Consortium-2 (VARC-2) major and life-threatening
bleeding12; (6) operation for any bleeding; (7) operation for any
peripheral bleeding; (8) postoperative hemoglobin nadir level;
and (9) postoperative hemoglobin drop during the index hospi-
talization. The definition of VARC-2 bleeding12 was based on
hemoglobin drop, the amount of RBC transfusions, and need of
any surgical, endovascular, or drainage procedure for excessive
bleeding. Data on the amount of blood transfusion were
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this information is considered complete in all patients.
Outcome Measures
The primary outcome of this study were 30-day and mid-
term all-cause mortality. The secondary outcomes were stroke,
acute kidney injury, de novo renal replacement therapy, atrial
fibrillation, and postoperative length of stay in the hospital
where the index procedure was performed. Stroke was defined
as any focal or global neurological deficit lasting 24 hours orTable 1
Characteristics of Patients Who Underwent Transcatheter Aortic Valve Replacemen
Characteristics Overall Series
1,818 patients
No RB
1,525 p
Age, mean (y) 81.6§6.4 81.5§6
Female, n (%) 1,030 (56.7) 831 (54
Body mass index, mean (kg/m2) 27.2 § 4.9 27.3 §
Hemoglobin, mean (g/dL) 12.5 § 1.5 12.7 §
Anemia, n (%) 829 (45.6) 638 (41
eGFR, mean (mL/min/1.73 m2) 66 § 23 66 § 2
Dialysis, n (%) 19 (1.0) 13 (0.9
Active malignancy, n (%) 290 (16.0) 58 (3.8
Diabetes, n (%) 497 (27.3) 423 (27
Transient ischemic attack or stroke, n (%) 321 (17.7) 266 (17
Pulmonary disease, n (%) 370 (20.4) 303 (19
Oxygen therapy, n (%) 10 (0.6) 9 (0.6)
Frailty GSS grades 2-3, n (%) 260 (14.3) 220 (14
Extracardiac arteriopathy, n (%) 277 (15.2) 222 (14
LVEF 50%, n (%) 471 (25.9) 402 (26
Atrial fibrillation, n (%) 785 (43.2) 666 (43
NYHA class 4, n (%) 207 (11.4) 161 (10
SPAP, n (%)
31-55 mmHg 747 (41.1) 620 (40
>55 mmHg 232 (12.8) 183 (12
Porcelain aorta, n (%) 82 (4.5) 68 (4.5
Coronary artery disease, n (%) 495 (27.2) 407 (26
Recent myocardial infarction, n (%) 40 (2.2) 30 (2.0
Acute heart failure 60 days/crit. preop. state, n (%) 208 (11.4) 161 (10
Prior PCI, n (%) 382 (21.0) 307 (20
Prior cardiac surgery, n (%) 313 (17.2) 272 (17
Permanent pace-maker, n (%) 175 (9.6) 154 (10
Urgent/emergency procedure, n (%) 129 (7.1) 94 (6.2
Concomitant PCI, n (%) 91 (5.0) 67 (4.4
Selected prostheses,* n (%) 1,329 (73.1) 1,157 (
Surgical femoral a. access, n (%) 290 (16.0) 225 (14
Antithrombotic treatment
Aspirin, n (%) 884 (48.6) 713 (46
Warfarin, n (%) 661 (36.4) 563 (36
NOAC, n (%) 81 (4.5) 73 (4.8
Heparin, n (%) 113 (6.2) 84 (5.5
Clopidogrel/ticagrelor, n (%) 252 (13.9) 198 (13
Dual antiplatelet treatment, n (%) 178 (9.8) 135 (8.
EuroSCORE II, mean (%) 6.7 § 6.9 6.4 § 6
STS Score, mean (%) 4.5 § 3.2 4.3 § 2
NOTE. Continuous variables are reported as means § standard deviation. Categoric
EuroSCORE II definition criteria.
Abbreviations: CABG, coronary artery bypass grafting; CI, confidence interval; eGF
Geriatric Status Scale; LVEF, left ventricular ejection fraction; NOAC; new oral an
SPAP, systolic pulmonary artery pressure.
* Indicates selected valve prostheses were the following third generation TAVR plonger with a new brain infarct or hemorrhage detected at neu-
roimaging, or a neurological deficit resulting in death. Further-
more, data on vascular complications as well as operations for
intrathoracic or peripheral bleeding were recorded. Major vas-
cular complications were defined according to the VARC-2
definition criteria.12 Acute kidney injury was defined accord-
ing to the Kidney Disease: Improving Global Outcomes classi-
fication criteria as any increase in serum creatinine 3.0 times
the baseline level or serum creatinine increase 26.5 mmol/L
and de novo renal replacement therapy during the index
hospitalization.13t and Predictors of Red Blood Cell Transfusion
C Transfusion
atients
RBC Transfusion
293 patients
Univariate
Analysis
p Value
Multivariate Analysis
Odds Ratio, 95% CI
.3 82.2§6.7 0.045
.5) 199 (67.9) <0.0001 1.56, 1.17-2.07
4.8 26.7 § 5.3 0.053
1.5 11.6 § 1.5 <0.0001 0.96, 0.95-0.96
.9) 191 (65.2) <0.0001 2.61, 1,99-3.42
2 62 § 24 0.001
) 6 (2.0) 0.065
) 13 (4.4) 0.289
.7) 74 (25.3) 0.383
.4) 55 (18.8) 0.585
.9) 67 (22.9) 0.243
1 (0.3) 1.000
.4) 40 (13.7) 0.729
.6) 55 (18.8) 0.066 1.51, 1.06-2.16
.4) 69 (23.6) 0.323
.7) 119 (40.6) 0.333
.6) 46 (15.7) 0.011
0.022
.7) 127 (43.3)
.0) 49 (16.7)
) 14 (4.8) 0.809
.7) 88 (30.0) 0.239
) 10 (3.4) 0.122
.6) 47 (16.1) 0.007
.1) 75 (25.6) 0.035
.8) 41 (14.0) 0.111
.1) 21 (7.2) 0.119
) 35 (11.9) <0.0001 1.59, 1.02-2.49
) 24 (8.2) 0.006
75.9) 172 (58.9) <0.0001 0.48, 0.37-0.63
.8) 65 (22.2) 0.001
.8) 171 (58.4) <0.0001 1.48, 1.14-1.94
.9) 98 (33.4) 0.258
) 8 (2.7) 0.118
) 29 (9.9) 0.004
.0) 54 (18.4) 0.013
9) 43 (14.7) 0.002
.3 8.3 § 9.3 <0.0001
.7 5.5 § 5.0 <0.0001
al variables as counts and percentages. Clinical variables are according to the
R, glomerular filtration estimated according to the MDRD equation; GSS,
ticoagulant; PCI, percutaneous coronary intervention; RBC, red blood cell;
rostheses and their variants: EvolutR, Sapien 3, Acurate Neo, and Lotus.
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Statistical analysis was performed using SAS statistical
package, version 9.2 (SAS Institute Inc, Cary, NC), SPSS v.
25.0 statistical software (IBM Corporation, New York) and
Stata v. 15.1 statistical software (StataCorp LLC, Texas). Sta-
tistical analyses were performed by the senior author (F.B.)
with large experience in biostatistics and by a biostatistician
(S.R.) with expertise in cardiovascular diseases. The normal
distribution of continuous variables was assessed with the Sha-
piro-Wilk test, which showed that none of the continuous vari-
ables but baseline hemoglobin were normally distributed. The
Mann-Whitney U test, Student’s t test, Fisher’s exact test, and
chi-square test were used for univariate analysis. Time trend
was assessed by the linear-by-linear association test. Logistic
regression with backward selection was used to identify the
risk factors independently associated with RBC transfusion
including in the regression model the covariates with p < 0.05
in univariate analysis as listed in Table 1. Extracardiac arterio-
pathy was forced in to this model. Discrimination and calibra-
tion of the logistic regression models were estimated by the
Hosmer-Lemeshow’s test and the receiver operating character-
istics (ROC) curve analysis. Cox proportional hazards analyses
with backward selection were employed for risk estimation of
mid-term mortality. The identified risk factors are as follows,
and they were employed for all risk adjusted analysis: age,
gender, baseline hemoglobin level, baseline estimated glomer-
ular filtration rate, diabetes, pulmonary disease, oxygen ther-
apy, atrial fibrillation, GSS frailty grades 2-3, active
malignancy, urgent or emergency procedure, left ventricular
ejection fraction 50%, and third generation prostheses. The
proportional hazards assumption was met according to the test
based on Schoenfeld residuals (p = 0.578), as well as by graph-
ical assessment of the ln-ln plot of the survival curves of
patients with and without blood transfusion adjusted for the
aforementioned covariates. Time-varying hazard ratios were
estimated for RBC transfusion, number of RBC unitsTable 2
Crude Rates and Risk Adjusted Estimates of Adverse Events in Patients Receiving o
Outcomes Overall Series
1,818 patients
No RBC Transfusion
1,525 patients
Mortality (%)
30-day 1.9 0.9
1-year 7.8 6.6
2-year 15.4 13.3
3-year 24.8 21.7
4-year 31.1 27.7
5-year 45.0 40.4
Stroke, n (%) 45 (2.5) 27 (1.8)
KDIGO acute kidney injury,* n (%) 105 (5.9) 55 (3.7)
Renal replacement therapy,* n (%) 8 (0.4) 2 (0.1)
Atrial fibrillation,y n (%) 109 (10.6) 77 (9.0)
Hospital stay, mean (d) 5.1 § 4.4 4.4 § 3.4
NOTE. Continuous variables are reported as means § standard deviation. Categoric
ratios, or coefficients with 95% CI.
Abbreviations: CI, confidence interval; KDIGO, Kidney Disease: Improving Global
* Indicates excluding patients with preoperative estimated glomerular filtration ra
y Indicates excluding patients with any preoperative atrial fibrillation.transfused, and more than 4 RBC units transfused or any oper-
ation for bleeding. Interaction tests for RBC transfusion with
anemia, coronary artery disease, surgical versus percutaneous
femoral artery access, selected third generation prostheses,
and STS score <3% or >3% were performed with a statistical
significance set at p < 0.1. Mixed-effect logistic regression
was performed to estimate the risk of 30-day mortality
adjusted for the aforementioned covariates and any interinsti-
tutional differences in patient blood management. A one-to-
one propensity score matching was performed to adjust the
cohorts of patients who received or not received RBC transfu-
sion for baseline and operative covariates using the nearest
neighbor method with a caliper of 0.2 of the standard deviation
of the logit of the propensity score (ie, 0.2). A propensity score
was calculated by including the covariates listed in Table 1.
After matching, the authors evaluated the balance between the
matched cohorts with analysis of the standardized differences. A
standardized difference 0.10 was considered as an acceptable
balance between the study cohorts. Paired tests were used to com-
pare the outcomes of interest in these matched cohorts. All tests
were two-sided and p< 0.05 was set for statistical significance.Results
Study Population and Main Outcomes
The FinnValve registry includes data from 6,463 patients
who underwent primary TAVR (2,130 patients) and surgical
aortic valve replacement (4,333 patients) with a bioprosthesis
for severe AS. Out of 2,130 TAVR patients, no data on blood
transfusion were available in 35 patients and were excluded
from this study. After excluding patients who underwent
TAVR through nontransfemoral accesses, 1,818 patients were
selected for this analysis. The characteristics of these patients
are summarized in Table 1, and the main outcomes of this
series are summarized in Table 2. During the study period, 293
patients (16.1%) received RBC transfusion and the time-trendr Not Blood Transfusions After Transcatheter Aortic Valve Replacement
RBC Transfusion
293 patients
Univariate Analysis
p Value
Adjusted Analysis
Risk Estimate, 95% CI
<0.0001 1.57, 1.23-2.00
6.8
13.6
25.0
37.7
44.3
60.5
18 (6.1) <0.0001 3.97, 2.02-7.82
50 (17.7) <0.0001 5.54, 3.46-8.88
6 (2.1) <0.0001 16.13, 2.32-112.38
32 (18.4) <0.0001 2.18, 1.35-3.56
8.6 § 6.6 <0.0001 3.87, 3.34-4.39
al variables as counts and percentages. Risk estimates are odds ratios, hazard
Outcomes; RBC, red blood cell.
te <15 mL/min/m2 or dialysis.
Fig 1. Rates of blood transfusion along the study period.
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significantly through the years, from 27.5% in 2012 to 10.0%
in 2017 (linear-by-linear association test, p < 0.0001; Fig 1).Table 3
Crude Rates and Risk Adjusted Estimates of Adverse Events According to In
Replacement
Outcomes No RBC Transfusion
1,525 patients
RBC Tran
1-2 units
190 patien
Mortality (%)
30-day 0.9 2.6
1-year 6.6 8.1
2-year 13.3 19.2
3-year 21.7 32.6
4-year 27.7 41.4
5-year 40.4 58.0
Adjusted risk estimates Reference 1.16, 0.85
Stroke, n (%) 27 (1.8) 9 (4.7)
Adjusted risk estimates Reference 2.85, 1.24
KDIGO acute kidney injury,* n (%) 55 (3.7) 20 (10.7)
Adjusted risk estimates Reference 2.66, 1.44
Renal replacement therapy,* n (%) 2 (0.1) 1 (0.5)
Adjusted risk estimates Reference 1.66, 0.87
Atrial fibrillation,y n (%) 77 (9.0) 10 (8.8)
Adjusted risk estimates Reference 0.83, 0.41
Hospital stay, mean (d) 4.4 § 3.4 7.0 § 4.5
Adjusted risk estimates Reference 2.22, 1.61
NOTE. Continuous variables are reported as means § standard deviation. Categoric
ratios or coefficients with 95% confidence interval (CI).
Abbreviations: KDIGO, Kidney Disease: Improving Global Outcomes; RBC, red bl
* Indicates excluding patients with preoperative estimated glomerular filtration ra
y Indicates excluding patients with any preoperative atrial fibrillation.In brief, transfusion of 1 to 2, 3 to 4, and >4 RBC units
occurred in 10.5%, 2.8%, and 2.9% of patients, respectively.
Operation for intrathoracic for bleeding was performed in 0.6%creasing Amount of Blood Transfusions After Transcatheter Aortic Valve
sfusion
ts
RBC Transfusion
3-4 units
51 patients
RBC Transfusion
>4 units
52 patients
p Value
11.8 17.3
19.9 25.3
33.0 38.8
41.4 54.5
45.9 54.5
62.9 69.7
-1.58 2.00, 1.27-3.13 3.11, 2.05-4.72 <0.0001
1 (2.0) 8 (15.4)
-6.58 1.08, 0.14-8.34 11.47, 4.70-27.98 <0.0001
13 (26.5) 17 (37.0)
-4.91 8.31, 3.85-17.96 17.85, 8.62-36.95 <0.0001
2 (4.0) 3 (6.1)
-31.97 21.40, 1.90-241.46 61.66, 6.59-576.46 0.001
6 (21.4) 16 (50.0)
-1.71 2.57, 0.98-6.79 11.50, 5.36-24.68 <0.0001
10.5 § 7.5 12.7 § 9.5
-2.83 5.63, 4.52-6.72 7.86, 6.78-8.94 <0.0001
al variables as counts and percentages. Risk estimates are odds ratios, hazard
ood cell.
te <15 mL/min/m2 or dialysis.
Table 4
Risk Estimates of 30-Day and Late Mortality According to Different Parame-
ters of Perioperative Bleeding-Related Variables
Outcomes
30-day mortality Odds ratio, 95% CI
RBC transfusion 8.47, 3.86-18.60
VARC-2 severity of bleeding
None or minor bleeding Reference cat.
Major bleeding 2.15, 0.85-5.47
Life threatening bleeding 17.57, 7.37-41.89
Number of RBC units transfused (per unit) 1.48, 1.32-1.65
None Reference cat.
1-2 units 2.92, 0.97-8.84
3-4 units 14.82, 4.91-44.70
>4 units 22.98, 8.63-61.21
Transfusion of >4 RBC units or
operation for bleeding
7.35, 3.33-16.26
Any operation for bleeding 7.59, 3.18-18.13
Operation for peripheral bleeding 4.37, 1.57-12.13
Nadir hemoglobin (per g/dL) 0.94, 0.91-0.97
Drop in hemoglobin (per g/dL) 1.88, 1.41-2.52
Late mortality Hazard ratio, 95% CI
RBC transfusion 1.57, 1.23-2.00
VARC-2 severity of bleeding
None or minor bleeding Reference cat.
Major bleeding 1.02, 0.80-1.30
Life threatening bleeding 2.58, 1.86-3.58
Number of RBC units transfused (per unit) 1.20, 1.14-1.26
None Reference cat.
1-2 units 1.16, 0.85-1.58
3-4 units 2.00, 1.27-3.13
>4 units 3.11, 2.05-4.72
Transfusion of >4 RBC units
or operation for bleeding
2.12, 1.53-1.65
Any operation for bleeding 1.94, 1.30-2.88
Operation for peripheral bleeding 1.76, 1.23-2.51
Nadir hemoglobin (per g/dL) 0.98, 0.97-0.99
Drop in hemoglobin (per g/dL) 1.18, 1.08-1.29
Abbreviations; CI, 95% confidence interval; RBC, red blood cell.
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ing in 3.7% of patients, and any operation for bleeding in 4.2%
of patients. VARC-2 major bleeding occurred in 24.1% of
patients and VARC-2 life-threatening bleeding occurred in 6.0%
of patients. Reoperation for bleeding and transfusion of >4
RBC units was observed in 6.4% of patients. After TAVR, the
mean nadir hemoglobin level was 10.3 § 1.6 g/dL, and the
mean drop of hemoglobin level was 2.2 § 1.3 g/dL.
Logistic regression showed that female gender (19.3% v
11.9%), low baseline hemoglobin (mean, 11.6 v 12.7 g/dL),
extracardiac arteriopathy (19.9% v 15.5%), first-second gener-
ation prostheses versus third generation prostheses (24.6% v
13.0%), urgent/emergency procedure (27.1% v 15.3%), and
preoperative use of aspirin (19.4% v 13.1%) were independent
predictors of RBC transfusion after TAVR (Hosmer-
Lemeshow’s test, p = 0.478, area under the ROC 0.735, 95%
confidence interval [CI] 0.705-0.766) (Table 1). When anemia
was included into this regression model instead of baseline
hemoglobin, it was an independent predictor of RBC transfu-
sion (crude rates, 23.0% v 10.3%, odds ratio [OR] 2.61, 1.99-
3.42). Logistic regression model including the aforementioned
covariates along with any minor or major vascular complica-
tions according to the VARC-2 criteria showed that the latter
was associated with an excessive risk of RBC transfusion
(crude rates, 52.9% v 10.9%, OR 10.10, 95% CI 7.24-14.10).
Early Outcomes
RBC transfusion was associated with increased 30-day mor-
tality (crude rates, 6.8% v 0.9%, adjusted OR 8.47, 95% CI
3.86-18.60, missing data in 5 patients, 0.3%) (Table 2). When
the year of procedure was included in the regression model,
the risk estimate of RBC transfusion for 30-day mortality did
not change markedly (adjusted OR 8.49, 95% CI 3.85-18.87;
when adjusted for years 2008-2014 v 2015-2017: OR 8.41,
95% CI 3.82-18.50). Similarly, RBC transfusion increased the
risk of stroke, acute kidney injury, de novo renal replacement
therapy, new atrial fibrillation and prolonged hospital stay
(Table 2). The risk of these early adverse events increased
along with the amount of transfused RBC units also when
adjusted for multiple covariates (Table 3). Thirty-day mortal-
ity increased significantly with increasing amount of RBC
transfusion, particularly when operation for excessive bleeding
was necessary (Table 4). Consistently with these findings,
postoperative hemoglobin level drop and nadir were indepen-
dent predictors of 30-day mortality (Table 4).
Mixed-effect logistic regression adjusted for multiple varia-
bles and participating centers showed that 30-day mortality
was significantly increased in patients who received RBC
transfusion (OR 8.47, 95% CI 3.86-18.60) compared with
those who did not received RBC transfusion (Table 2). Simi-
larly, mixed-effect logistic regression showed that increasing
amounts of RBC transfusion (1-2 RBC units, OR 2.92, 95% CI
0.97-8.84; 3-4 RBC units, OR 14.82, 95% CI 4.91-44.70; >4
RBC units, OR 22.98, 95% CI 8.62-61.20) were associated
with increased 30-day mortality (Table 3).Late Outcome
The mean follow-up of this study was 2.0 § 1.6 years (range,
0-9.6 years). The adjusted impact of RBC transfusion, increasing
amount of RBC transfusion, VARC-2 major and life-threatening
bleeding, as well as transfusion of more than 4 units of RBC
and any operation for bleeding on late all-cause mortality are
summarized in Table 4 and Figure 2. When the year of proce-
dure was included into the regression model, the risk of late
mortality after RBC transfusion did not change markedly
(adjusted HR 1.56, 95% CI 1.22-2.01; when adjusted for years
2008-2014 v 2015-2017: HR 1.61, 95% CI 1.25-2.06). Late all-
cause mortality was increased significantly along with the
amount of transfused RBC units, particularly when operation for
excessive bleeding was necessary (Table 4). Consistent with
these findings, postoperative hemoglobin level drop and nadir
were independent predictors of late all-cause mortality (Table 4).
The time-varying hazard ratio for all-cause mortality
decreased markedly during the first year after the procedure
Fig 2. Adjusted late mortality according to RBC transfusion, and transfusion of more than 4 units of RBCs or any operation for bleeding. RBC, red blood cell.
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transfused as well as for transfusion of more than 4 units of
RBC, but then the negative prognostic impact of these varia-
bles remained constant along the years (Fig 3).
Interaction Analyses
Interaction tests showed that there was a significant interac-
tion between anemia and RBC transfusion in predicting 30-
day mortality (p = 0.088). No significant interaction was
observed between RBC transfusion and variables of interests
in predicting the primary outcomes.
Propensity Score Matching Analysis
Propensity score matching provided 281 pairs of patients
with all baseline covariates having a standardized difference
0.10 (Table 5), but coronary artery disease (standardized dif-
ference, 0.130, p = 0.124) and new oral anticoagulants (stan-
dardized difference, 0.199, p = 0.038). These matched cohorts
had similar STS score (mean, 5.2% v 5.3%, p = 0.429, stan-
dardized difference, 0.013) and EuroSCORE 2 (mean, 7.2% v
7.6%, p = 0.808, standardized difference, 0.048) (Table 5).
Among these propensity matched pairs, patients who received
RBC transfusion after TAVR had significantly increased risk
of 30-day (7.1% v 0%, p < 0.0001) and late mortality (at 5-
year, 59.1% v 43.3, p = 0.008), acute kidney injury, renal
replacement therapy, atrial fibrillation, as well as longerhospital stay (Table 6). Patients who received RBC transfusion
had a numerically increased risk of stroke (6.4 v 3.6%,
p = 0.170), but the difference did not reach statistical signifi-
cance (Table 6)
Discussion
The main findings of the present study are that: (1) despite
the high prevalence of anemia (46%), this nationwide study
showed that RBC transfusion was necessary in only 16% of
patients after TAVR; (2) the frequency of RBC transfusion
dramatically decreased during the years, likely because of
improved results with most recent TAVR prostheses and
changes in perioperative antithrombotic treatment; (3) preop-
erative anemia, extracardiac arteriopathy, and antithrombotic
therapy are potential targets to reduce the risk of perioperative
bleeding and RBC transfusion; (4) RBC transfusion after
TAVR is an independent predictor of early and late adverse
events; (5) the risk of adverse events was particularly evident
in patients who required multiple RBC transfusion and any
operation for bleeding; and (6) consistent with these findings,
postoperative hemoglobin level drop and its nadir were inde-
pendent predictors of early and late mortality.
Previous studies documented rates of blood transfusion after
TAVR of 25% to 39% in series with a prevalence of anemia
ranging from 45% to 57%.5-8 The present study documented a
rate of RBC transfusion of 16% in the context of a prevalence
of anemia of 46%. These figures suggested that, despite a lack
Fig 3. Time-varying hazard ratios for RBC transfusion, number of RBC units
transfused, and transfusion of more than 4 units of red blood cells, or any oper-
ation for bleeding. RBC, red blood cell.
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nationwide series the risk of severe bleeding requiring transfu-
sion was rather low and decreased over time. Similar findingswere observed in a recent study from the National Inpatient
Sample, which reported a rate of blood transfusion decreasing
from 30% in 2012 to 10% in 2015.3 Such improvements might
be secondary to the knowledge of the prognostic importance
of severe bleeding, which is thoroughly documented in adult
cardiac surgery, as well as to advances in patient selection,
transcatheter technology, and perioperative antithrombotic
policies. Indeed, a drop in the use of blood transfusion was
observed particularly from 2015 to 2017 along with the intro-
duction of third generation TAVR prostheses and likely with
consolidated experience with this procedure in all participating
centers. However, in Finland a drop in blood transfusions was
observed during the last few years also after surgical aortic
valve replacement,2 and this might be related to improved,
reduced perioperative blood losses and patient blood manage-
ment during the recent years.
It is worth noting that herein extracardiac arteriopathy and
access site bleeding requiring operative treatment were inde-
pendent predictors of blood transfusion. These findings suggest
that adequate planning of the access site is of crucial impor-
tance to prevent significant bleeding and to reduce the expo-
sure to blood products. Still, in the setting of significant
atherosclerosis of the iliac and femoral arteries, transaortic
access might not reduce the risk of perioperative bleeding.14 A
recent study showed a rate of blood transfusion as high as 30%
also with the transcaval approach.15 Early experience suggests
that transcarotid access,16 but not the trans-subclavian
access,17 may reduce the risk of major bleeding after TAVR.
In the near future, further studies on extra-femoral peripheral
access will elucidate whether these routes may reduce the risk
of vascular complications and perioperative bleeding.
The prevalence of anemia in patients undergoing TAVR
may reach 60%,18 and it is associated with higher risk of blood
transfusion and mortality.19 Intuitively, preprocedural treat-
ment of anemia could seem a sound policy to prevent perioper-
ative anemia and the need for blood transfusion. However, the
efficacy and safety of treating anemia before TAVR is contro-
versial,20,21 and further studies are needed to get conclusive
results on the efficacy of this important component of patient
blood management.
The negative prognostic effect of blood transfusion has been
largely demonstrated in cardiac surgery,22 whereas only a few
studies of small size investigated this issue in patients undergo-
ing TAVR.4-8,23,24 This setting provides important advantages in
investigating the effect of transfusions in patients undergoing
cardiovascular interventions. Indeed, the minimally invasive
nature of TAVR allows a more reliable evaluation of the effects
of perioperative anemia and blood transfusion without the con-
founding effect of significant hemodilution and other detrimental
effects of cardiopulmonary bypass seen in patients undergoing
cardiac surgery. Herein, the authors have demonstrated that the
negative effect of blood transfusion was independent of other
significant comorbidities as shown by regression analyses
adjusted by significant comorbidities (Tables 2 and 3), as well
as by propensity score matching analysis (Tables 5 and 6). The
evidence of a prognostic effect of postoperative nadir and drop
of hemoglobin on the early and late mortality further
Table 5
Characteristics of Propensity Score Matched Pairs of Patients Who Received or Not Blood Transfusions After Transcatheter Aortic Valve Replacement
Characteristics No RBC Transfusion
281 patients
RBC Transfusion
281 patients
Univariate
Analysis
p Value
Standardized Differences
Age, mean (y) 82.1 § 6.5 82.1 § 7.8 0.818 0.006
Female, n (%) 188 (66.9) 189 (67.3) 0.928 0.008
Body mass index, mean (kg/m2) 26.9 § 5.1 26.8 § 5.3 0.787 0.024
Hemoglobin, mean (g/dL) 116 § 14 117 § 15 0.562 0.051
Anemia, n (%) 188 (66.9) 179 (63.7) 0.425 0.067
eGFR, mean (mL/min/1.73 m2) 63 § 24 62 § 24 0.726 0.006
Dialysis, n (%) 5 (1.8) 5 (1.8) 1.000 0.000
Active malignancy, n (%) 14 (5.0) 13 (4.6) 0.844 0.017
Diabetes, n (%) 72 (25.6) 68 (24.2) 0.696 0.039
Transient ischemic attack or stroke, n (%) 52 (18.5) 53 (18.9) 0.914 0.009
Pulmonary disease, n (%) 58 (20.6) 62 (22.1) 0.681 0.035
Oxygen therapy, n (%) 2 (0.7) 1 (0.4) 0.563 0.049
Frailty GSS grades 2-3, n (%) 38 (13.5) 39 (13.9) 0.902 0.010
Extracardiac arteriopathy, n (%) 45 (16.0) 53 (18.9) 0.374 0.075
LVEF 50%, n (%) 63 (22.4) 64 (22.8) 0.920 0.009
Atrial fibrillation, n (%) 99 (35.2) 112 (39.9) 0.257 0.096
NYHA class 4, n (%) 35 (12.5) 39 (13.9) 0.618 0.042
SPAP, n (%) 0.889 0.041
31-55 mmHg 126 (44.8) 123 (43.8)
>55 mmHg 39 (13.9) 43 (15.3)
Porcelain aorta, n (%) 10 (3.6) 13 (4.6) 0.523 0.053
Coronary artery disease, n (%) 98 (34.9) 81 (28.8) 0.124 0.130
Recent myocardial infarction, n (%) 10 (3.6) 10 (3.6) 1.000 0.000
Acute heart failure 60 days/crit. preop. state, n (%) 41 (14.6) 40 (14.2) 0.904 0.010
Prior PCI, n (%) 71 (25.3) 70 (24.9) 0.922 0.008
Prior cardiac surgery, n (%) 31 (11.0) 38 (13.5) 0.368 0.076
Permanent pace-maker, n (%) 21 (11.0) 21 (11.0) 1.000 0.000
Urgent/emergency procedure, n (%) 30 (10.7) 28 (10.0) 0.782 0.023
Concomitant PCI, n (%) 23 (8.2) 22 (7.8) 0.876 0.013
Selected prostheses,* n (%) 173 (61.6) 169 (60.1) 0.730 0.029
Surgical femoral a. access, n (%) 57 (20.3) 58 (20.6) 0.917 0.009
Antithrombotic treatment
Aspirin, n (%) 178 (63.3) 118 (58.0) 0.195 0.109
Warfarin, n (%) 86 (30.6) 93 (33.1) 0.526 0.053
NOAC, n (%) 1 (0.4) 8 (2.8) 0.038 0.199
Heparin, n (%) 29 (10.3) 24 (8.5) 0.470 0.061
Clopidogrel/ticagrelor, n (%) 50 (17.8) 49 (17.4) 0.912 0.009
Dual antiplatelet treatment, n (%) 41 (14.6) 38 (13.5) 0.716 0.030
EuroSCORE II, mean (%) 7.2 § 6.9 7.6 § 7.9 0.808 0.048
STS Score, mean (%) 5.2 § 3.6 5.3 § 4.6 0.429 0.013
NOTE. Continuous variables are reported as means § standard deviation. Categorical variables as counts and percentages. Clinical variables are according to the
EuroSCORE II definition criteria.
Abbreviations: CABG, coronary artery bypass grafting; CI, confidence interval; eGFR, glomerular filtration estimated according to the MDRD equation; GSS,
Geriatric Status Scale; LVEF, left ventricular ejection fraction; NOAC; new oral anticoagulant; PCI, percutaneous coronary intervention; RBC, red blood cell;
SPAP, systolic pulmonary artery pressure.
* Indicates selected valve prostheses were the following third generation TAVR prostheses and their variants: EvolutR, Sapien 3, Acurate Neo, and Lotus.
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ratio analysis showed that the adjusted risk of all-cause mortality
decreased during the first year after the procedure for any RBC
transfusion, increasing amount of RBC units transfused, as well
as for transfusion of more than 4 units of RBC, but later the
negative prognostic impact of these variables remained constant
along the years (Fig 3).
The present analysis confirmed that blood transfusion, par-
ticularly when multiple RBC units are transfused or operation
for bleeding was necessary, increases the risk of stroke andacute kidney injury (Tables 2 and 3). Blood transfusion is a
well-known risk factor for acute kidney injury in patients
undergoing TAVR,5,23,24 but less is known about its impact on
stroke.23,25 These 2 end-organ complications may share the
same pathogenetic mechanisms possibly triggered by reduced
oxygen delivery secondary to severe anemia, as well as
immune-mediated reactions associated with blood transfusion.
These early end-organ complications are in turn associated
with increased risk of late mortality. The transfusion-related
immunomodulation may further compromise the recovery of
Table 6
Adverse Events in Propensity Score Matched Pairs of Patients Who Received or Not Blood Transfusions After Transcatheter Aortic Valve Replacement
Outcomes No RBC Transfusion
281 patients
RBC Transfusion
281 patients
Univariate Analysis
p Value
Mortality (%) 0.008
30-day 0 7.1 <0.0001
1-year 5.9 13.5
2-year 12.7 24.9
3-year 22.8 36.0
4-year 25.3 43.0
5-year 43.3 59.1
Stroke, n (%) 10 (3.6) 18 (6.4) 0.170
KDIGO acute kidney injury,* n (%) 12 (4.4) 46 (17.0) <0.0001
Renal replacement therapy,* n (%) 1 (0.4) 10 (3.6) <0.0001
Atrial fibrillation,y n (%) 79 (28.1) 111 (39.5) 0.005
Hospital stay, mean (d) 4.7 § 3.0 8.5 § 6.2 <0.0001
NOTE. Continuous variables are reported as means § standard deviation, as well as median and interquartile range. Categorical variables as counts and
percentages. Risk estimates are odds ratios, hazard ratios, or coefficients with 95% confidence interval (CI).
Abbreviations: CI, confidence interval; KDIGO, Kidney Disease: Improving Global Outcomes; RBC, red blood cell.
* Indicates excluding patients with preoperative estimated glomerular filtration rate <15 mL/min/m2 or dialysis.
y Indicates excluding patients with any preoperative atrial fibrillation.
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acute, and chronic effects on macrophage function.26
The present study has some limitations inherent to all retro-
spective analyses. RBC transfusions were performed without
prespecified treatment criteria and the magnitude of bias cannot
be determined at this stage. However, these results suggest that
the risk of adverse events increased when multiple RBC units
were transfused and when any operation for excessive bleeding
was necessary. Furthermore, separate analyses showed that both
nadir and drop of hemoglobin levels were independent predic-
tors of early and late mortality, which suggest the prognostic
importance of perioperative anemia. Indeed, contrary to patients
undergoing surgical aortic valve replacement, the risk of hemo-
dilution secondary to fluid therapy is minimal in patients under-
going TAVR and any postoperative drop of hemoglobin level
occurring in these patients mostly reflects the amount of periop-
erative blood loss. Despite these limitations, this nationwide reg-
istry provides data from a rather large number of unselected
patients offering an excellent view to evaluate the results of
TAVR. Data retrieved from a central national registry strength-
ened the validity of survival analyses.
In conclusion, this nationwide registry showed that, despite
a high prevalence of preoperative anemia, TAVR can be per-
formed with a rather low rate of RBC transfusion. RBC trans-
fusion had a significant impact on early and mid-term
outcomes of these patients, and the adverse effects were partic-
ularly evident with increasing amount of RBC transfusions and
operations for excessive bleeding. These findings suggest there
is a need of studies evaluating the efficacy and safety of pre-
procedural treatment of anemia, and strategies to reduce access
site bleeding during TAVR.Conflict of interest
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